Insulin therapy in type 2 diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 4, 2001, Pages 935-982

  Mudaliar, Sunder ^a,b   Edelman, Steven V ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0035159416     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70222-X     Document Type: Article

References (75)

1. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes
2. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM)
3. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: Results from the DIGAMI study
4. The pharmacologic treatment of hyperglycemia in NIDDM
5. Clinical Practice Recommendations, American Diabetes Association, 1999
6. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus
7. Insulin therapy in obese NIDDM induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal
8. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
9. For the IOEZ study group: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c
10. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes
11. Basic mechanisms and very low calorie diets
12. Insulin resistance in obese and nonobese man (clinical review 26)
13. Inhaled human insulin treatment in patients with type 2 diabetes mellitus
14. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial
15. Hypoglycemia (technical review)
16. Futility of self-monitoring of blood glucose without algorithms for adjusting insulin doses
17. Pathogenesis of NIDDM: A balanced overview
18. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding
19. Implantable nsulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus
20. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus
21. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes
22. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus
23. Evaluations of retinopathy in the VA Cooperative. Study on Glycemic Control and Complications in Type 2 Diabetes (VA CSDM): A feasibility study
24. Obesity and lipoprotein disorders
25. Feasibility of adjustment of insulin dose by insulin-requiring type 2 diabetic patients
26. The effect of insulin treatment on insulin action and insulin secretion in type 2 diabetes mellitus
27. Insulin use in NIDDM
28. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors
29. The beta cell function in NIDDM patients with secondary failure: A three year follow-up of combined oral hypoglycemic and insulin therapy
30. Different effects of insulin and oral anti-diabetic agents on glucose and energy metabolism in type 2 diabetes mellitus
31. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults
32. Starting insulin therapy in patients with type 2 diabetes: Effectiveness, complications, and resource utilization
33. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
34. Intensive conventional insulin therapy for type 2 diabetes: Metabolic effects during a 6 month outpatient trial
35. Diabetes and cardiovascular risk factors: The Framingham Study
36. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM
37. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type 2 diabetic patients poorly controlled with sulfonylureas
38. Insulin therapy in type 2 diabetes
39. Pharmacokinetics dynamics of subcutaneous injection of long-acting human insulin glargine in type 1 diabetes mellitus
40. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus
41. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus
42. Therapeutic approaches to insulin resistance
43. New oral therapies for type 2 diabetes-glitazones as insulin sensitizers
44. Inhaled Insulin for type 2 diabetes [editorial]
45. Medical hazards of obesity
46. Multicentre trial of a programmable implantable insulin pump in type 1 diabetes
47. C-peptide as a measure of the secretion and hepatic extraction of insulin: Pitfalls and limitations
48. Rosiglitazone improves glucose control in poorly controlled, insulin treated patients with type 2 diabetes mellitus
49. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
50. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study
51. Efficacy of bedtime NPH insulin with daytime sulfonylurea for sub-population of type 2 diabetes subjects
52. Evening insulin strategy
53. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone
54. Dose-response characteristics for effects of insulin on production and utilization of glucose in man
55. Glucose toxicity: The implications of hyperglycemia in the pathophysiology of diabetes mellitus
56. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
57. Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition
58. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: A randomized clinical trial
59. Insulin treatment reverses the insulin resistance of type 2 diabetes
60. Bedtime insulin/daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM
61. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients
62. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin
63. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease
64. Insulin use in NIDDM: Rationale based on pathophysiology of disease
65. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
66. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
67. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry
68. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
69. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
70. Less nocturnal hypoglycemia and better post dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during combination therapy in type 2 diabetes
71. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
72. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus
73. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: A randomized, controlled trial
74. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
75. The NIDDM epidemic: Global estimates and projection: A look into the crystal ball